Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nanalysis Scientific Corp. NSCIF


Primary Symbol: V.NSCI

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The Company’s segments include Scientific Equipment and Security Services. Scientific Equipment segment conducts scientific equipment manufacturing and sales, primarily as a patent-protected technology Company that develops... see more

TSXV:NSCI - Post Discussion

Nanalysis Scientific Corp. > Research Capital updates and raises
View:
Post by Possibleidiot01 on Nov 11, 2021 6:42am

Research Capital updates and raises

cantechletter.com

kneat.com has momentum behind it, says Eight Capital

Eight Capital analyst Christian Sgro is increasingly optimistic about kneat.com (kneat.com Stock Quote, Chart, News TSXV:KSI), maintaining his “Buy” rating while raising his target price to $5.40/share from $4.75/share, leading to a projected return of 34 per cent in an update to clients on Wednesday.

Headquartered in Ireland, kneat.com designs, develops and supplies software for data and document management through its kneat Gx platform, an application focused on validation lifecycle management and testing for the biotechnology, pharmaceutical and medical device manufacturing industries.

Sgro’s latest company analysis comes after kneat released its third quarter financial results, which Sgro noted to be more impressive than its previous quarter despite muted reaction.

“Similar to last quarter, we expect momentum to continue as kneat scales, uplists to the TSX, and delivers on plan,” Sgro said. “The company has proven product-market fit, with a land and expand strategy that we believe remains in the early innings.”

HIRE Technologies

The company’s results were headlined by $3.7 million in revenue to produce year-over-year growth of 91 per cent, with a substantial increase in SaaS revenue ($2.6 million, 276 per cent increase) driving that figure forward. kneat’s gross margin percentage remained relatively steady at 54.3 per cent, while adjusted EBITDA came in at a loss of $1.1 million.  

Sgro had a number of takeaways from the company’s conference call to discuss the reports, including the fact that none of its customers have fully scaled their operations yet, meaning this kind of quarter is repeatable through continued R&D investment and step-function expansion.

In addition, Sgro noted that kneat has started getting referrals from customers to their supply chain partners, which in turn has led to more opportunities to strengthen its overall market; he also noted that some of the company’s partners are shouldering bigger responsibilities in the development process, which should prove beneficial for kneat in the long term as it relates to its gross margin.

“New customer acquisition and the expansion of existing customers continue to drive our growth,” said Eddie Ryan, Chief Executive Officer of kneat in the company’s November 9 press release. “As customers scale their use of kneat, our technology is becoming an integral part of their operations. While our growth trajectory continues upward, these large scaling events are somewhat unpredictable in their timing and given the early growth stage of the company, they can result in period-to-period variability in ARR growth rates.”

“I’m very proud of our dedicated employees as they continue to execute across all functions, ensuring ongoing growth and value creation for our shareholders,” Ryan added.

The newest results have encouraged Sgro to alter some of his financial projections for kneat, raising his fourth quarter revenue projection to $4.6 million from $3.9 million to mark a 55.7 per cent year-over-year increase, with the lion’s share of the difference coming from SaaS license fees. 

Consequently, Sgro’s 2021 overall revenue projection is now $13.8 million, an upgrade from the previous $13 million estimate, and representing a potential year-over-year increase of 86.6 per cent. The 2022 revenue projection also enjoys a bump up, as Sgro now forecasts $23.9 million for a 72.8 per cent potential year-over-year increase compared to the original estimate of $21.1 million. The revised numbers all come in ahead of the consensus estimates of $4 million in the fourth quarter, $13 million in 2021 and $21.3 million in 2022.

Meanwhile, Sgro has added further adjusted EBITDA losses to his projections for kneat, forecasting a loss of $800,000 in the fourth quarter (in line with the consensus estimate) compared to the previous estimate of a $300,000 loss, leading to a modified projection of a $3 million overall loss in 2021 compared to the original $1.8 million estimate, which puts it below the consensus estimate of a $2.6 million loss.

In addition, Sgro has included another year of negative adjusted EBITDA as he has revised his 2022 projection to a $1.4 million loss compared to the initial thought of going positive at $600,000, all while remaining below the consensus projection of a $300,000 loss.

With the negative adjusted EBITDA values present, the only valuation multiple Sgro looks at for kneat is the EV/Revenue multiple, which he projects to drop from the reported 38.9x in 2020 to a projected 20.8x in 2021, then again to a projected 12.1x in 2022, all of which compare favourably to the averages in Sgro’s high-growth B2B SaaS peer groups in Canada (15.1x in 2022) and the United States (20.5x in 2022). 

 

Overall, kneat.com’s stock price is up 44.3 per cent for the year to date, maintaining its momentum after beginning its upswing in late July that eventually reached a peak of $4.64/share on September 13.

  •  
  •  
  •  

About The Author /

Comment by Possibleidiot01 on Nov 12, 2021 4:30pm
it would help if I posted the right article. By Geordie Carragher November 10, 2021 Filed under:   All posts, Analysts, Life Sciences Stock:   NSCI Nanalysis Scientific scores target raise from Research Capital Research Capital Corporation analyst Yue (Toby) Ma continues to look favourably upon Nanalysis ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities